Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts-Reference-Cited by-同舟云学术

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts

Published:2019-12-30 Issue:2 Volume:111 Page:536-547
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Bang Yung‐Jue¹^ORCID,Su Wu‐Chou²,Schuler Martin³,Nam Do‐Hyun⁴,Lim Wan Teck⁵,Bauer Todd M.⁶,Azaro Analia⁷⁸,Poon Ronnie Tung Ping⁹,Hong David¹⁰,Lin Chia‐Chi¹¹^ORCID,Akimov Mikhail¹²,Ghebremariam Samson¹³,Zhao Sylvia¹⁴,Giovannini Monica¹³,Ma Brigette¹⁵

Affiliation:

1. Seoul National University College of Medicine Seoul Korea

2. National Cheng Kung University Hospital Tainan Taiwan

3. Department of Medical Oncology West German Cancer Center University Duisburg‐Essen and German Cancer Consortium (DKTK), Partner Site University Hospital Essen Essen Germany

4. Samsung Medical Center Seoul Korea

5. National Cancer Centre Singapore

6. Sarah Cannon Research Institute/Tennessee Oncology PLLC Nashville Tennessee USA

7. Department of Medical Oncology Molecular Therapeutics Research Unit Vall d’Hebron University Hospital Barcelona Spain

8. Pharmacology Department The Autonomous University of Barcelona (UAB) Barcelona Spain

9. Queen Mary Hospital Hong Kong China

10. University of Texas/MD Anderson Cancer Center Houston Texas USA

11. National Taiwan University Hospital Taipei Taiwan

12. Novartis Pharma AG Basel Switzerland

13. Novartis Pharmaceuticals Corporation East Hanover New Jersey USA

14. China Novartis Institutes for BioMedical Research Shanghai China

15. State Key Laboratory of Translational Oncology, Phase 1 Clinical Trial Centre The Chinese University of Hong Kong Hong Kong China

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14254

Reference38 articles.

1. c-MET as a potential therapeutic target and biomarker in cancer

2. Amplification ofMETmay identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

3. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

4. MET As a Possible Target for Non–Small-Cell Lung Cancer

5. IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MET Oncogene Targeting for Cancer Immunotherapy;International Journal of Molecular Sciences;2024-06-01

2. Advances in MET tyrosine kinase inhibitors in gastric cancer;Cancer Biology & Medicine;2024-05-10

3. Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions;Cells;2024-01-25

4. MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature;Therapeutic Advances in Medical Oncology;2024-01

5. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review;Cancers;2023-07-10